Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17909221 | 1.00 | TSHR (0.50) | TSHRALDH1A1EPHX2LMNAMAPT | |
| SCHEMBL16707218 | 0.88 | TSHR (0.58) | TSHRALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL17908830 | 0.85 | LMNA (0.52) | TSHRALDH1A1EPHX2LMNAMAPT | |
| SCHEMBL17909443 | 0.85 | LMNA (0.52) | TSHRALDH1A1EPHX2LMNAMAPT | |
| SCHEMBL14179962 | 0.84 | TSHR (0.45) | TSHRALDH1A1EPHX2LMNAMAPT | |
| SCHEMBL4430084 | 0.84 | TSHR (0.70) | TSHRALDH1A1EPHX2LMNAMAPT | |
| SCHEMBL13686344 | 0.84 | LMNA (0.44) | TSHRALDH1A1EPHX2LMNAMAPT | |
| SCHEMBL14148186 | 0.82 | TSHR (0.56) | TSHRALDH1A1LMNAKMT2AL3MBTL1 | |
| SCHEMBL17909115 | 0.82 | CYP1A2 (0.47) | TSHRALDH1A1EPHX2LMNAMAPT | |
| SCHEMBL17908651 | 0.82 | CYP1A2 (0.47) | TSHRALDH1A1EPHX2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3048093-B1 | ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF | MORESCO CORP (JP) | 2019-02-20 | — | — | EP | disclosed |
| US-10077229-B2 | Ether-containing monoester compound and use thereof | MORESCO CORPORATION (JP) | 2018-09-18 | — | — | US | disclosed |
| EP-3048093-A1 | ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF | Moresco Corporation (JP) | 2016-07-27 | — | — | EP | disclosed |
| US-20160200998-A1 | ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF | MORESCO CORPORATION (JP) | 2016-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077229-B2 | Ether-containing monoester compound and use thereof | SFN, CCNE2, HSD3B2 | TSHR 4877/4885ALDH1A1 1635/4885EPHX2 200/4885 |
| US-20160200998-A1 | ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF | SFN, CCNE2, MSMO1 | TSHR 4877/4885ALDH1A1 1563/4885EPHX2 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.